1. HBW Insight
  2. >>Wellness
  3. >>Policy & Regulation
  4. >>Legal

‘Clinically Proven’ Claim Leaving RB's Brain Health Supplements In US Class Action Settlement

 
• By Eileen Francis

Settlement in Southern District of Florida federal court includes a consolidated class action complaint against UK firm’s US businesses comprising cases in Florida, New York and California – filed in 2020 over statements the products were “clinically proven” to improve “brain performance” including focus, memory, learning, accuracy, concentration and reasoning.

brain life
RB's BRAND NAME NEURIVA COMBINES THE GREEK WORD FOR BRAIN WITH THE LATIN WORD FOR LIFE.

Reckitt Benckiser Group PLC will soften clinical claims on labeling and marketing for its Neuriva brain health supplement line and will pay up to $8m in a class action settlement.

The settlement in the US District Court for the Southern District of Florida in Miami ends litigation initially filed a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal

FDA RIF Delays Response On NPA NMN Petition

 
• By Malcolm Spicer

Due to staff reductions at FDA ordered by DOGE, but accounting for return of some employees after their dismissals were rescinded, agency missed July 31 deadline it had set for responding to the NPA’s petition and expects to respond by Sept. 30.

NAD Asks FTC To Pull Bandage Off Firm’s Plan To Exhaust Inventory Using ‘2X Faster Healing’ Claim

 
• By Malcolm Spicer

After National Advertising Division attorneys, in a review prompted by a challenge by Band-Aid line marketer Kenvue, recommended ASO LLV cease use of its “up to 2x faster healing” claim, they determined the firm had not fully complied.

Supreme Court 1935 Ruling Limiting Executive Authority On Appointments ‘Unravels’ Today – DoJ

 
• By Malcolm Spicer

In complaint and response to motion to dismiss, Rebecca Kelly Slaughter’s and Alvaro Bedoya’s attorneys elaborate on Supreme Court ‘s 1935 decision, Humphrey’s Executor v. US. Administration attorneys, though, contend the ruling isn’t relevant to the current FTC.

Loper Bright Could Trip FDA On Self-Affirmed GRAS

 
• By Malcolm Spicer

Instead of arguing FDA’s not authorized to offer option under authority from 1958 Food Additives Amendments, potential litigation could contend the law requires agency to continue making self-GRAS without notification available.

More from Policy & Regulation

US FDA’s Kratom Focus Pivots To ‘Concentrated Synthetic Byproduct That Is An Opioid’

 
• By Malcolm Spicer

Explaining he was a heroin addict for 14 years more than 40 years ago “because it was so available,” Secretary Kennedy says “our agencies have been asleep in the wheel” but “now we're going to wake up and we're going to start to stop this before it starts.”

EU Green Claims Directive: Commission Says It ‘Has Not Withdrawn’ From Negotiations

 
• By David Ridley

What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.

US FDA Extracts More Evidence To Ban Kratom

 
• By Malcolm Spicer

Recent warning letters to seven companies marketing products with kratom extract known as 7-OH are FDA’s first in three years referencing unlawful products containing kratom and the first of all its kratom-related warnings to reference extracts from the botanical.